UCB upgrades 2026 guidance on strong US Bimzelx sales
Today 06:10
UCB upgrades 2026 guidance on strong US Bimzelx sales Oct 22 (Reuters) - Belgian biopharmaceutical group UCB UCB.BR upgraded its 2026 financial guidance on Thursday, driven by the stronger performance of its blockbuster drug Bimzelx in the US.
The company expects adjusted earnings before interest, taxes, depreciation and amortization growth in the low- to mid-forties at constant exchange rates, up from previous guidance of mid-teens to low-twenties.
(Reporting by Lucie Barbier)
((Email: lucie.barbier@thomsonreuters.com))
Recent news on UCB SA
See all newsUCB tops STOXX after guidance upgrade on better drug sales
UCB upgrades 2026 guidance on strong US Bimzelx sales (updated)
UCB upgrades 2026 guidance on strong US Bimzelx sales
Brief: UCB Eyes Low- To Mid-Forties FY Adjusted EBITDA Growth
Brief: UCB Annouces FDA Approval For Zilbrysq Autoinjector Self-Administration For Adults Living With Generalized Myasthenia Gravis